Arbutus Biopharma wins patent ruling against Moderna

A U.S. District Court in Delaware issued a memorandum and order on February 2, 2026, in patent litigation between Arbutus Biopharma Corporation (NASDAQ: ABUS) and Moderna Inc. regarding COVID-19 vaccine technology.

The case involves Arbutus and its licensee Genevant Sciences GmbH seeking damages from Moderna for alleged infringement of six U.S. patents in the manufacture and sale of MRNA-1273, Moderna's COVID-19 vaccine.

The patents in question are numbered 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378. The court's memorandum and order was issued in the U.S. District Court for the District of Delaware.

The information is based on a press release statement from Arbutus Biopharma.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• Healthcare Triangle, Inc (HCTI) files for 28M share offering by selling stockholders
• Cognizant shareholder derivative settlement gets preliminary approval